FINWIRES · TerminalLIVE
FINWIRES

$SMMT

8 stories mentioning SMMT

Every FINWIRES story that references SMMT, newest first.

Insider Trading

Summit Therapeutics Insider Bought Shares Worth $49,987,200, According to a Recent SEC Filing

Robert W Duggan, 10% Owner, Director, Co-Chief Executive Officer, on June 12, 2026, executed a purchase for 3,810,000 shares in Summit Therapeutics (SMMT) for $49,987,200. Following the Form 4 filing with the SEC, Duggan has control over a total of 610,015,809 common shares of the company, with 573,883,879 shares held directly and 36,131,930 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1599298/000105591926000007/xslF345X05/wk-form4_1781281727.xmlPrice: $13.62, Change: $+0.54, Percent Change: +4.09%

$SMMT
Wire

Summit Therapeutics Withdraws Public Offering Due to Market Conditions

Summit Therapeutics (SMMT) has withdrawn its proposed underwritten public offering of securities, due to market conditions, the company said in a Thursday regulatory filing.The company had announced the launch of an underwritten public offering of $500 million of its common stock on Tuesday.Price: $13.49, Change: $+0.43, Percent Change: +3.33%

$SMMT
Insider Trading

Summit Therapeutics Insider Bought Shares Worth $722,250, According to a Recent SEC Filing

Manmeet Singh Soni, Director, COO and CFO, on June 04, 2026, executed a purchase for 50,000 shares in Summit Therapeutics (SMMT) for $722,250. Following the Form 4 filing with the SEC, Soni has control over a total of 3,123,603 common shares of the company, with 3,123,603 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1599298/000156976926000004/xslF345X05/wk-form4_1780605646.xml

$SMMT
Wire

Summit Therapeutics Says Ivonescimab Improves Survival Over Tislelizumab in Phase III Lung Cancer Trial

Summit Therapeutics' (SMMT) ivonescimab in combination with chemotherapy demonstrated a significant overall survival benefit over tislelizumab plus chemotherapy in the Phase III HARMONi-6 trial in previously untreated patients with advanced squamous non-small cell lung cancer, the company said Sunday.The company said ivonescimab reduced the risk of death by 34%, with patients receiving the drug plus chemotherapy achieving longer median overall survival and higher 24-month survival rates than those treated with tislelizumab plus chemotherapy.The survival benefit was consistent across both PD-L1-negative and PD-L1-positive patient groups. The study had previously met its primary endpoint of progression-free survival, the company added.The China-based trial, led by Akeso, showed no new safety concerns. Results were presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in The Lancet.Summit Therapeutics shares were up over 4% in Monday premarket activity.Price: $18.41, Change: $+0.87, Percent Change: +4.97%

$SMMT
Wire

BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says

BioNTech's (BNTX) cancer-drug pipeline is showing stronger early results and is approaching several important clinical milestones, improving confidence in the company's long-term outlook, UBS Securities said Wednesday in a report.BioNTech is developing a new type of cancer medicine designed to both activate the immune system and cut off a tumor's blood supply, and early data from the company's lead program, pumitamig, in lung cancer have been encouraging in studies conducted in China and globally, with safety results that appear manageable, the report said.BioNTech's broader cancer pipeline remains under-recognized, and pumitamig may become competitive in several difficult-to-treat cancers, including triple-negative breast cancer and colorectal cancer, the report said. Global trial results look similar to early data from China, easing investor concerns that the treatment might not work the same way across regions, UBS said.A key moment for the field will come at the upcoming American Society of Clinical Oncology meeting, where Akeso and Summit Therapeutics (SMMT) will present overall survival data from their HARMONi-6 study, the report said. Strong results would help validate the drug approach BioNTech is pursuing and may shift sentiment around the company's oncology strategy, UBS said.UBS upgraded its rating on BioNTech stock to buy from neutral and raised its price target to $135 from $117.Price: $93.33, Change: $+1.08, Percent Change: +1.17%

$BNTX$SMMT
Wire

Summit Therapeutics Shares Fall After HC Wainwright Downgrade

Summit Therapeutics (SMMT) shares fell nearly 2% in intraday trading on Friday after HC Wainwright downgraded the stock to neutral from buy.Trading volume stood at about 4.2 million shares, compared with a daily average of over 3.4 million.Price: $17.15, Change: $-0.32, Percent Change: -1.83%

$SMMT
Research

Bernstein Initiates Summit Therapeutics at Underperform

Summit Therapeutics (SMMT) has an average rating of overweight and mean price target of $28.51, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SMMT
Research

HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy

Summit Therapeutics (SMMT) has an average rating of overweight and mean price target of $28.51, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SMMT